PreeteshJainMD

PubMed

• 61 citations
  Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chron...
  Preetesh Jain, Hagop M. Kantarjian, Mona Lisa Alattar, Elias Jabbour, Koji Sasaki
  The Lancet. Haematology. 2015-03-01
• 38 citations
  TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
  Vivian Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai
  Molecular Cancer. 2022-09-26
• 77 citations
  A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
  Christoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, Viktoria Blumenberg, Maria-Luisa Schubert
  Nature Medicine. 2023-04-01

Abstracts/Posters

• Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy
  Preetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all